Jonathan Aschoff analyst ROTH MKM

Currently out of the existing stock ratings of Jonathan Aschoff, 115 are a BUY (91.27%), 6 are a HOLD (4.76%), 5 are a SELL (3.97%).

Jonathan Aschoff

Work Performance Price Targets & Ratings Chart

Analyst Jonathan Aschoff, currently employed at ROTH MKM, carries an average stock price target met ratio of 44.77% that have a potential upside of 42.94% achieved within 128 days. Previously, Jonathan Aschoff worked at BREAN.

Jonathan Aschoff’s has documented 224 price targets and ratings displayed on 44 stocks. The coverage is on Healthcare, Energy, Consumer Cyclical sectors.

Most recent stock forecast was given on BFRI, Biofrontera at 07-Oct-2024.

Wall Street Analyst Jonathan Aschoff

Analyst best performing recommendations are on PBLA (PANBELA THERAPEUTICS).
The best stock recommendation documented was for PBLA (PANBELA THERAPEUTICS) at 12/18/2023. The price target of $25 was fulfilled within 1 day with a profit of $4.8 (23.76%) receiving and performance score of 237.62.

Average potential price target upside

ALXN Alexion Pharmaceuticals APDN Applied DNA Sciences APVO Aptevo Therapeutics INCY yte INO Inovio Pharmaceuticals MBRX Moleculin Biotech SEEL Seelos Therapeutics TFFP Tff Pharmaceuticals VVUS VIVUS CLDX Celldex Therapeutics PGNX Progenics Pharmaceuticals REGN Regeneron Pharmaceuticals AZRX AzurRx BioPharma CMRX Chimerix BPTH Bio Path Holdings FWBI First Wave BioPharma NOVN Novan REVB Revelation Biosciences KMPH KemPharm AKBA Akebia Ther BFRI Biofrontera CLRB Cellectar Biosciences HRTX Heron Therapeuti ACER Acer Therapeutics TTPH Tetraphase Pharmaceuticals CYCC Cyclacel Pharmaceuticals PBLA Panbela Therapeutics OTRK Ontrak BRTX BioRestorative Therapies CELZ Creative Medical Technology Holdings ALDR Alder BioPharmaceuticals ETTX Entasis Therapeutics Holdings EYEN Eyenovia INMB INmune Bio MNMD Mind Medicine  RMTI Rockwell Medical CLNN Clene HSDT Helius Medical Technologies MRTX Mirati Ther NOV NOV OCGN Ocugen SEE Sealed Air VBLT Vascular Biogenics Ltd NUWE Nuwellis

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold Since 03-May-2021

$173

$-9.5 (-5.21%)

$156

Hold Since 04-Feb-2021

$190

$7.5 (4.11%)

$190

Buy Since 06-Sep-2019

$175

$-7.5 (-4.11%)

$165

Buy Since 17-Jul-2017

$166

$-16.5 (-9.04%)

$175

Show more analysts

Please expand the browser size to see the chart

What Year was the first public recommendation made by Jonathan Aschoff?

On 2008

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?